GSK to co-market generics with Dr. Reddy’s
pharmafile | June 17, 2009 | News story | Sales and Marketing |Â Â Dr Reddy, GSK, em, genericsÂ
GlaxoSmithKline will increase its reach into emerging markets with a new deal to co-market generics with Dr. Reddy’s.
The Indian company is one of the world’s best known generics companies, but GSK’s sales and marketing might will help generate more revenue for it.
Around 100 products will be manufactured by Dr. Reddy’s, and licensed and supplied by GSK.
They will be co-marketed in some countries and it is not known how revenue from the venture will be shared.
The agreement excludes Dr Reddy’s home market of India, but takes in various countries in Africa, the Middle East, Asia-Pacific and South America.
The new move is part of a strategy “to further accelerate sales growth in emerging markets” which has seen GSK involved in a string of collaborations around the world in recent times.
“This is another significant step forward in our strategy to grow and diversify GSK’s business in emerging markets,” said Abbas Hussain, GlaxoSmithKline’ president, emerging markets.
“Growth in both population and economic prosperity is leading to increased demand for branded pharmaceuticals. Together we will be able to deliver more medicines of value to more patients in these countries.”
No financial details have been released, but GSK will gain exclusive access to Dr. Reddy’s “rich and diverse” portfolio.
Cardiovascular, diabetes, oncology, gastroenterology and pain management treatments are among those included in the deal.
Dr Reddy’s said the move would “fully realise the potential of our strengths in technology, product development and manufacturing”.
“We hope to take our purpose of providing affordable and innovative medicines to a much wider population through this partnership,” said Dr. Reddy’s chief executive GV Prasad.
GSK’s similar activities include this month’s flu vaccine manufacturing arrangement for China, Hong Kong and Macau with Shenzhen Neptunus Interlong Bio-Technique.
And last month it bought a 16% stake in South Africa-based Aspen Pharmacare Holdings as part of a collaboration in sub-Saharan Africa.
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …
